GT Biopharma Inc. (GTBP)
NASDAQ: GTBP
· Real-Time Price · USD
1.49
0.15 (11.19%)
At close: Aug 18, 2025, 10:48 AM
GT Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -13.21M | -14.36M | -13.77M | -13.29M | -13M | -13.58M | -16.19M | -20.09M | -19.48M | -21.26M | -33.66M | -32.59M | -33.95M | -57.52M | -41.53M | -37.52M | -34.7M |
Interest Income | 292K | 402K | 523K | 643K | 758K | 780K | 741K | 632K | 448K | 292K | 157K | 82K | 46K | 38K | 32K | n/a | n/a |
Pretax Income | -11.67M | -13.16M | -12.35M | -11.35M | -9.64M | -7.6M | -10.22M | -14.68M | -15.67M | -20.88M | -33.32M | -31.89M | -33.78M | -58.01M | -54.92M | -52.35M | -56.27M |
Net Income | -11.67M | -13.16M | -12.35M | -11.35M | -9.64M | -7.6M | -10.22M | -14.68M | -15.67M | -20.88M | -33.32M | -31.89M | -33.78M | -58.01M | -54.92M | -52.35M | -64.91M |
Selling & General & Admin | 7.08M | 8.57M | 8.54M | 8.01M | 7.41M | 7.11M | 8.23M | 10.76M | 11.11M | 12.45M | 21.38M | 22.05M | 23.92M | 47.92M | 38.01M | 35.09M | 32.9M |
Research & Development | 6.12M | 5.8M | 5.22M | 5.28M | 5.59M | 6.47M | 7.95M | 9.33M | 8.37M | 8.81M | 12.27M | 10.54M | 10.04M | 9.59M | 3.52M | 2.43M | 1.8M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 13.21M | 14.36M | 13.77M | 13.29M | 13M | 13.58M | 16.19M | 20.09M | 19.48M | 21.26M | 33.66M | 32.59M | 33.95M | 57.52M | 41.53M | 37.52M | 34.7M |
Interest Expense | n/a | n/a | n/a | n/a | 1K | 213K | 221K | 221K | 220K | 8K | 22K | 22K | 22K | 718K | -2.21M | -1.28M | 3.38M |
Selling & Marketing Expenses | n/a | n/a | 285K | 285K | 285K | 285K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 13.21M | 14.36M | 13.77M | 13.29M | 13M | 13.58M | 16.19M | 20.09M | 19.48M | 21.26M | 33.66M | 32.59M | 33.95M | 57.52M | 41.53M | 37.52M | 34.7M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 2.35M | 1.9M | 2.23M | 1.71M | 1.38M | 1.38M | 1.37M | 1.34M | 1.08M | 1.18M | 8.65M | 1.04M | 1.08M | 8.65M | 1.05M | 1.12M | 541.33K |
Shares Outstanding (Diluted) | 2.35M | 1.9M | 2.23M | 1.71M | 1.38M | 1.38M | 1.37M | 1.34M | 1.08M | 1.18M | 8.65M | 1.04M | 1.08M | 8.65M | 1.05M | 1.12M | 541.33K |
EPS (Basic) | -6.02 | -7.33 | -7.49 | -7.73 | -7.05 | -5.62 | -8.19 | -7.19 | -8.56 | -13.37 | -10.73 | -15.17 | -16.66 | -66.54 | -67.78 | -63.21 | -60.94 |
EPS (Diluted) | -6.02 | -7.33 | -7.49 | -7.73 | -7.05 | -5.62 | -8.19 | -7.19 | -8.56 | -13.37 | -10.73 | -15.17 | -16.66 | -66.54 | -67.78 | -63.21 | -60.94 |
EBITDA | -12.83M | -10.07M | -9.26M | -8.26M | -6.54M | -7.38M | -10M | -14.46M | -15.45M | -20.88M | -33.3M | -31.87M | -33.75M | -57.3M | -54.23M | -50.72M | -49.98M |
EBIT | -12.83M | -13.16M | -12.35M | -11.35M | -9.63M | -7.38M | -10M | -14.46M | -15.45M | -20.88M | -33.3M | -31.87M | -33.75M | -57.3M | -54.23M | -50.72M | -49.98M |
Depreciation & Amortization | n/a | 3.09M | 3.09M | 3.09M | 3.09M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1K | 2K | 3K |